Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

Molecular and Cellular Biology

Volumn 15, Issue 3, 1995, Pages 1613-1619

  Asai, Naoya ^a   Iwashita, Toshihide ^a   Matsuyama, Mutsushi ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CELL SURFACE PROTEIN; COMPLEMENTARY DNA; GENE PRODUCT;

ANIMAL CELL; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CELL STRAIN 3T3; CELL TRANSFORMATION; GENE ACTIVATION; GENE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; SIPPLE SYNDROME;

ANIMALIA; CYTOMEGALOVIRUS; SIMIAE; SIMIAN VIRUS; SIMIAN VIRUS 40;

EID: 0028838086     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/mcb.15.3.1613     Document Type: Article

References (30)

1. Asai, N., et al. Unpublished results.
2. 1a. Avantaggiato, V., N. A. Dathan, M. Grieco, N. Fabien, D. Lazzaro, A. Fusco, A. Simeone, and M. Santoro. 1994. Developmental expression of the RET protooncogene. Cell Growth Differ. 5:305-311.
3. Carlson, K. M., S. Dou, D. Chi, N. Scavarda, K. Toshima, C. E. Jackson, S. A. Wells, P. J. Goodfellow, and H. Donis-Keller. 1994. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA 91:1579-1583.
4. Coulier, F., R. Kumar, M. Ernst, R. Klein, D. Martin-Zanca, and M. Barbacid. 1990. Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain. Mol. Cell. Biol. 10:4202-4210.
5. Donis-Keller, H., S. Dou, D. Chi, K. M. Carlson, K. Toshima, T. C. Lairmore, J. R. Howe, J. F. Moley, P. Goodfellow, and S. A. Wells. 1993. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2:851-856.
6. Edery, P., S. Lyonnet, L. M. Mulligan, A. Pelet, E. Dow, L. Abel, S. Holder, C. Nihoul-Fekete, B. A. J. Ponder, and A. Munnich. 1994. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (London) 367:378-380.
7. Eng, C., D. P. Smith, L. M. Mulligan, M. A. Nagai, C. S. Healey, M. A. Ponder, E. Gardner, G. F. W. Scheumann, C. E. Jackson, A. Tunnacliffe, and B. A. J. Ponder. 1994. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum. Mol. Genet. 3:237-241.
8. Hofstra, R. M. W., R. M. Landsvater, I. Ceccherini, R. P. Stulp, T. Stelwagen, Y. Luo, B. Pasini, J. W. M. Hoppener, H. K. P. van Amstel, G. Romeo, C. J. M. Lips, and C. H. C. M. Buys. 1994. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (London) 367:375-376.
9. Ikeda, I., Y. Ishizaka, T. Tahira, T. Suzuki, M. Onda, T. Sugimura, and M. Nagao. 1990. Specific expression of the ret proto-oncogene in human neuroblastoma cell lines. Oncogene 5:1291-1296.
10. Iwamoto, T., M. Taniguchi, N. Asai, K. Ohkusu, I. Nakashima, and M. Takahashi. 1993. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene 8:1087-1091.
11. 9a. Iwashita, T., et al. Unpublished data.
12. Kuma, K., N. Iwabe, and T. Miyata. 1993. Motifs of cadherin- and fibronectin type III-related sequences and evolution of the receptor tyrosine kinases: sequence similarity between proto-oncogene ret and cadherin family. Mol. Biol. Evol. 10:539-551.
13. Maruyama, S., T. Iwashita, T. Imai, H. Funahashi, I. Ceccherini, Y. Luo, G. Romeo, S. Matsuo, M. Matsuyama, and M. Takahashi. 1994. Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B. Jpn. J. Cancer Res. 85:879-882.
14. Mulligan, L. M., C. Eng, C. S. Healey, D. Clayton, J. B. J. Kwok, E. Gardner, M. A. Ponder, A. Frilling, C. E. Jackson, H. Lehnert, H. P. H. Neumann, S. N. Thibodeau, and B. A. J. Ponder. 1994. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genet. 6:70-74.
15. Mulligan, L. M., J. B. J. Kwok, C. S. Healey, M. J. Elsdon, C. Eng, E. Gardner, D. R. Love, S. E. Mole, J. K. Moore, L. Papi, M. A. Ponder, H. Telenius, A. Tunnacliffe, and B. A. J. Ponder. 1993. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature (London) 363:458-460.
16. 2+ binding site of uvomorulin abolish the adhesive function. Cell 63:1033-1038.
17. Pachnis, V., B. Mankoo, and F. Costantini. 1993. Expression of the ret proto-oncogene during mouse embryogenesis. Development 119:1005-1017.
18. Romeo, G., P. Ronchetto, Y. Luo, V. Barone, M. Seri, I. Ceccherini, B. Pasini, R. Bocciardi, M. Lerone, H. Kaariainen, and G. Martucciello. 1994. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature (London) 367:377-378.
19. Roussel, M. F., J. R. Downing, C. W. Rettenmier, and C. J. Sherr. 1988. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell 55:979-988.
20. Santoro, M., R. Rosati, M. Grieco, M. T. Berlingieri, G. L.-C. D'Amato, V. de Franciscis, and A. Fusco. 1990. The ret proto-oncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5:1595-1598.
21. Schneider, R. 1992. The human protooncogene ret: a communicative cadherin? Trends Biochem. Sci. 17:468-469.
22. Schuchardt, A., V. D'Agati, L. Larsson-Blomberg, F. Constantini, and V. Pachnis. 1994. Defect in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature (London) 367:380-383.
23. Takahashi, M., N. Asai, T. Iwashita, T. Isomura, K. Miyazaki, and M. Matsuyama. 1993. Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 8:2925-2929.
24. Takahashi, M., Y. Buma, and H. Hiai. 1989. Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence. Oncogene 4:805-806.
25. Takahashi, M., Y. Buma, T. Iwamoto, Y. Inaguma, H. Ikeda, and H. Hiai. 1988. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 3:571-578.
26. Takahashi, M., Y. Buma, and M. Taniguchi. 1991. Identification of the ret proto-oncogene products in neuroblastoma and leukemia cells. Oncogene 6:297-301.
27. Tsuzuki, T., M. Takahashi, N. Asai, T. Iwashita, M. Matsuyama, and J. Asai. 1995. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10:191-198.
28. Watowich, S. S., A. Yoshimura, G. D. Longmore, D. J. Hilton, Y. Yoshimura, and H. F. Lodish. 1992. Homodimerization and constitutive activation of the erythropoietin receptor. Proc. Natl. Acad. Sci. USA 89:2140-2144.
29. Woolford, J., A. McAuliffe, and L. R. Rohrshneider. 1988. Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. Cell 55:965-977.
30. Yoshimura, A., G. Longmore, and H. F. Lodish. 1990. Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity. Nature (London) 348:647-649.